Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiency

NCT02860559 is registered in ClinicalTrials.gov with Taiga Biotechnologies, Inc. as lead sponsor.

NCT NCT02860559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02860559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiency
Lead sponsor
Taiga Biotechnologies, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
August 31, 2021
Completion date
March 31, 2024
Enrollment
8 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

severe combined immunodeficiency